52 research outputs found
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Get PDFThe combination of gemcitabine plus bevacizumab produced a 21% response rate and a median survival of 8.8 months in a multicenter phase II trial in patients with metastatic pancreatic cancer. These encouraging data led Cancer and Leukemia Group B (CALGB) to conduct a double-blind, placebo-controlled, randomized phase III trial of gemcitabine/bevacizumab versus gemcitabine/placebo in advanced pancreatic cancer patients
Outcomes of biliary stents in advanced pancreatic cancer in the era of improved systemic therapy.
No full text
Multiplatform molecular profiling of 2,400 pancreatic adenocarcinomas to identify targets for therapeutic intent.
No full textInhibition of poly (ADP-ribose) polymerase-1 (PARP-1) to increase radiosensitivity of human pancreatic cancer (PAC) cell lines proficient in homology-directed repair (HDR).
No full textThe impact of chemotherapy on hospitalizations and emergency care in older adults with advanced cancer.
No full textAssociation between skin toxicities and treatment outcomes in patients with pancreatic cancer (PC) receiving erlotinib (E): Memorial Sloan-Kettering Cancer Center (MSKCC) experience.
No full textBreast cancer resistance protein (ABCG2) as a potential biomarker for gemcitabine and nab-paclitaxel sensitivity.
No full textTreatment, outcomes, and clinical trial participation in very elderly patients (pts) with metastatic pancreas cancer (mPC).
No full textJANUS 2: A phase III study of survival, tumor response, and symptom response with ruxolitinib plus capecitabine or placebo plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) who failed or were intolerant to first-line chemotherapy.
No full text- …
